Anti-Hepatitis C Virus Compound Library

Cat. No. : CS-L073 (261 compounds)
Library Contents: PDF | SDF

Hepatitis C virus (HCV) is a hepatotropic enveloped positive- strand RNA virus (family Flaviviridae) that infects the parenchymal cells of the liver. HCV infection is a significant public health burden. Globally, an estimated 71 million people have chronic hepatitis C virus infection. A significant number of those who are chronically infected will develop cirrhosis or liver cancer. To date, there is no vaccine against HCV, and combination pegylated alpha interferon (pIFN-) and ribavirin, the main standard-of-care treatment for HCV, is effective in only a subset of patients and is associated with a wide spectrum of toxic side effects and complications. More recently, new therapeutic approaches that target essential components of the HCV life cycle have been developed, including direct-acting antiviral (DAA) that specifically block a viral enzyme or functional protein and host-targeted agents (HTA) that block interactions between host proteins and viral components that are essential to the viral life cycle. However, the genetic diversity of HCV viruses and the stage of liver disease (i.e., cirrhosis) are revealing themselves as obstacles for effective, pan-genotypic treatments. There still exists a need for the discovery and development of new HCV inhibitors. In particular, since the future of HCV therapy will likely consist of a cocktail approach using multiple inhibitors that target different steps of infection, new antivirals targeting all steps of the viral infection cycle.

MCE offers a unique collection of 261 compounds with identified and potential anti-HCV activity. MCE Anti- Hepatitis C Virus Compound Library is a useful tool for discovery new anti-HCV drugs and other anti-infection research.

Size (Pre-dissolved DMSO or Solid) Stock Price
30 μL/well (10 mM solution) In-stock Get quote
50 μL/well (10 mM solution) In-stock Get quote
100 μL/well (10 mM solution) In-stock Get quote
250 μL/well (10 mM solution) In-stock Get quote
Products are for research use only. Not for human use. We do not sell to patients.

Bulk Inquiry

Collapse
Your information is safe with us. * Required Fields
  Salutation:
* Country or Region:
* Applicant name:
* Organization Name:
* Email address:
* Requested quantity:
* Phone number:
  Remarks:
 
Please slide the slider!
>>
 
Name, 
Organization name, 
Email address, 
Requested quantity, 
Phone number, 

Request SDF File

x

Please enter your email address. We will send your requested SDF file to you as soon as possible.

  • Data Sheet

  • Description & Advantages

  • Composition

  • Contents

Formulation:A collection of 261 compounds with anti-HCV activity supplied as pre-dissolved Solutions or Solid
Container:96- or 384-well Plate with Peelable Foil Seal; 96-well Format Sample Storage Tube With Screw Cap and Optional 2D Barcode
Storage:-80°C
Shipping:Blue ice

•   A unique collection of 261 bioactive anti-hepatitis C virus compounds for high throughput screening (HTS) and high content screening (HCS).

•   Targets include NS3, NS4A, NS5A, RNA-dependent RNA-polymerases, EGFR, etc.

•   A useful tool for the discovery of anti-HCV drugs.

•   Bioactivity and safety confirmed by preclinical research and clinical trials. Some have been approved by FDA.

•   Structurally diverse, medicinally active, and cell permeable.

•   Detailed compound information with structure, IC50, and brief introduction.

•   Validated NMR and HPLC to ensure high purity and quality.

•   All compounds are in stock and continuously updated.

PDF
Browsing History

    Customize Your Library

    You can select:
    • Specific Compounds
    • Quantities
    • Plate map
    • Concentration
    • Format (Solid or DMSO Solution)

    Please contact us at sales@chemscene.com

    Recommend Products
    CS-L022P Cat. No. : CS-L022P

    (3036 compounds)

    FDA-Approved Drug Library Plus

    CS-L139 Cat. No. : CS-L139

    (1711)

    Pain-Related Compound Library

    CS-L039 Cat. No. : CS-L039

    (1843 compounds)

    Reprogramming Compound Library